Cargando…

Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand

INTRODUCTION: Aldo-keto reductase 1C3 (AKR1C3) is known for multiple functions including its catalytic activity towards producing extra-testicular androgen. The present study is towards understanding interaction between biological, lifestyle and genetic impacts of AKR1C3 and their influence on clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Karunasinghe, Nishi, Symes, Eva, Gamage, Amy, Wang, Alice, Murray, Pam, Zhu, Shuotun, Goudie, Megan, Masters, Jonathan, Ferguson, Lynnette R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534310/
https://www.ncbi.nlm.nih.gov/pubmed/31125365
http://dx.doi.org/10.1371/journal.pone.0217373
_version_ 1783421387553112064
author Karunasinghe, Nishi
Symes, Eva
Gamage, Amy
Wang, Alice
Murray, Pam
Zhu, Shuotun
Goudie, Megan
Masters, Jonathan
Ferguson, Lynnette R.
author_facet Karunasinghe, Nishi
Symes, Eva
Gamage, Amy
Wang, Alice
Murray, Pam
Zhu, Shuotun
Goudie, Megan
Masters, Jonathan
Ferguson, Lynnette R.
author_sort Karunasinghe, Nishi
collection PubMed
description INTRODUCTION: Aldo-keto reductase 1C3 (AKR1C3) is known for multiple functions including its catalytic activity towards producing extra-testicular androgen. The present study is towards understanding interaction between biological, lifestyle and genetic impacts of AKR1C3 and their influence on clinical factors in a prostate cancer (PC) cohort from New Zealand (NZ). METHOD: Characteristics of 516 PC patients were collected from the Auckland Regional Urology Facility, NZ. These men were genotyped for the AKR1C3 rs12529 single nucleotide polymorphism (SNP). The leukocyte AKR1C3 activity was measured in a sub-cohort. Variability of leukocyte AKR1C3 activity between biological, lifestyle and clinical features as well as correlation between biological and clinical features were assessed with and without genetic stratification. RESULTS: The leukocyte AKR1C3 activity was associated with age at diagnosis (0.51 vs 0.34 μM coumberol units for >69y vs ≤69y, P = 0.03); and with anatomic stage/prognostic grouping among the AKR1C3 rs12529 CC genotype carriers (0.50 vs 28 μM coumberol units among low- and high-risk groups respectively, P = 0.02). Significant correlation between leukocyte AKR1C3 activity and age at PC diagnosis was also observed (correlation coefficient 0.20 and P = 0.02). Ever- smoking impacted both age and PSA at PC diagnosis among AKR1C3 rs12529 GG and CG genotype carriers respectively. Age at diagnosis significantly correlated with PSA at diagnosis in the main (correlation coefficient 0.29, and P<0.001) and sub-cohorts (correlation coefficient 0.24, and P = 0.01); and those carrying the AKR1C3 rs12529 CG and GG genotypes in both the main (correlation coefficient 0.30, and P<0.001 and correlation coefficient 0.35, and P<0.001 respectively) and sub-cohorts (correlation coefficient 0.43, and P<0.001 and correlation coefficient 0.39, and P = 0.06 respectively); but not with those carrying the CC genotype. CONCLUSIONS: Age dependent PSA thresholds in PC screening could have been valid only in men carrying the AKR1C3 rs12529 CG and GG genotypes in this NZ cohort.
format Online
Article
Text
id pubmed-6534310
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-65343102019-06-05 Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand Karunasinghe, Nishi Symes, Eva Gamage, Amy Wang, Alice Murray, Pam Zhu, Shuotun Goudie, Megan Masters, Jonathan Ferguson, Lynnette R. PLoS One Research Article INTRODUCTION: Aldo-keto reductase 1C3 (AKR1C3) is known for multiple functions including its catalytic activity towards producing extra-testicular androgen. The present study is towards understanding interaction between biological, lifestyle and genetic impacts of AKR1C3 and their influence on clinical factors in a prostate cancer (PC) cohort from New Zealand (NZ). METHOD: Characteristics of 516 PC patients were collected from the Auckland Regional Urology Facility, NZ. These men were genotyped for the AKR1C3 rs12529 single nucleotide polymorphism (SNP). The leukocyte AKR1C3 activity was measured in a sub-cohort. Variability of leukocyte AKR1C3 activity between biological, lifestyle and clinical features as well as correlation between biological and clinical features were assessed with and without genetic stratification. RESULTS: The leukocyte AKR1C3 activity was associated with age at diagnosis (0.51 vs 0.34 μM coumberol units for >69y vs ≤69y, P = 0.03); and with anatomic stage/prognostic grouping among the AKR1C3 rs12529 CC genotype carriers (0.50 vs 28 μM coumberol units among low- and high-risk groups respectively, P = 0.02). Significant correlation between leukocyte AKR1C3 activity and age at PC diagnosis was also observed (correlation coefficient 0.20 and P = 0.02). Ever- smoking impacted both age and PSA at PC diagnosis among AKR1C3 rs12529 GG and CG genotype carriers respectively. Age at diagnosis significantly correlated with PSA at diagnosis in the main (correlation coefficient 0.29, and P<0.001) and sub-cohorts (correlation coefficient 0.24, and P = 0.01); and those carrying the AKR1C3 rs12529 CG and GG genotypes in both the main (correlation coefficient 0.30, and P<0.001 and correlation coefficient 0.35, and P<0.001 respectively) and sub-cohorts (correlation coefficient 0.43, and P<0.001 and correlation coefficient 0.39, and P = 0.06 respectively); but not with those carrying the CC genotype. CONCLUSIONS: Age dependent PSA thresholds in PC screening could have been valid only in men carrying the AKR1C3 rs12529 CG and GG genotypes in this NZ cohort. Public Library of Science 2019-05-24 /pmc/articles/PMC6534310/ /pubmed/31125365 http://dx.doi.org/10.1371/journal.pone.0217373 Text en © 2019 Karunasinghe et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Karunasinghe, Nishi
Symes, Eva
Gamage, Amy
Wang, Alice
Murray, Pam
Zhu, Shuotun
Goudie, Megan
Masters, Jonathan
Ferguson, Lynnette R.
Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand
title Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand
title_full Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand
title_fullStr Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand
title_full_unstemmed Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand
title_short Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand
title_sort interaction between leukocyte aldo-keto reductase 1c3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from new zealand
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534310/
https://www.ncbi.nlm.nih.gov/pubmed/31125365
http://dx.doi.org/10.1371/journal.pone.0217373
work_keys_str_mv AT karunasinghenishi interactionbetweenleukocytealdoketoreductase1c3activitygenotypesbiologicallifestyleandclinicalfeaturesinaprostatecancercohortfromnewzealand
AT symeseva interactionbetweenleukocytealdoketoreductase1c3activitygenotypesbiologicallifestyleandclinicalfeaturesinaprostatecancercohortfromnewzealand
AT gamageamy interactionbetweenleukocytealdoketoreductase1c3activitygenotypesbiologicallifestyleandclinicalfeaturesinaprostatecancercohortfromnewzealand
AT wangalice interactionbetweenleukocytealdoketoreductase1c3activitygenotypesbiologicallifestyleandclinicalfeaturesinaprostatecancercohortfromnewzealand
AT murraypam interactionbetweenleukocytealdoketoreductase1c3activitygenotypesbiologicallifestyleandclinicalfeaturesinaprostatecancercohortfromnewzealand
AT zhushuotun interactionbetweenleukocytealdoketoreductase1c3activitygenotypesbiologicallifestyleandclinicalfeaturesinaprostatecancercohortfromnewzealand
AT goudiemegan interactionbetweenleukocytealdoketoreductase1c3activitygenotypesbiologicallifestyleandclinicalfeaturesinaprostatecancercohortfromnewzealand
AT mastersjonathan interactionbetweenleukocytealdoketoreductase1c3activitygenotypesbiologicallifestyleandclinicalfeaturesinaprostatecancercohortfromnewzealand
AT fergusonlynnetter interactionbetweenleukocytealdoketoreductase1c3activitygenotypesbiologicallifestyleandclinicalfeaturesinaprostatecancercohortfromnewzealand